Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Public ClinicalTrials.gov record NCT02286921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open label study to determine if treatment with intramuscular T given on a dose/schedule designed to result in rapid cycling from the polar extremes of supraphysiologic to near castrate levels \[i.e. Bipolar Androgen Therapy (BAT)\] will improve primary and secondary objectives vs. enzalutamide as standard therapy.
Study identification
- NCT ID
- NCT02286921
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 222 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2015 (Type not available)
- Primary completion
- Oct 26, 2018 (Actual)
- Completion
- Feb 21, 2020 (Actual)
- Last update posted
- Nov 6, 2020
2015 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 16
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Unversity of Alabama | Birmingham | Alabama | 35294 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Piedmont Cancer Institute | Atlanta | Georgia | 30318 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center | Kansas City | Kansas | 66160 | — |
| Tulane University Medical Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| SKCCC at Johns Hopkins | Baltimore | Maryland | 21205 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Neraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Washing | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02286921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02286921 live on ClinicalTrials.gov.